MMP19 and diabetic kidney disease: This paradigm shift in understanding RASi pharmacology, from traditional antihypertensives to multi-target modulators of cellular degradation, redox balance, and inflammatory signaling, unveils unprecedented therapeutic avenues for DKD management, fundamentally reshaping treatment strategies through molecular precision medicine approaches.